In-Hospital Outcomes of Revascularization in Patients with Left Ventricular Systolic Dysfunction and Coronary Chronic Total Occlusion
DOI:
https://doi.org/10.59958/hsf.7637Keywords:
percutaneous coronary intervention, coronary artery bypass grafting, left ventricular systolic dysfunction, chronic total occlusionAbstract
Background: The in-hospital outcomes of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with left ventricular systolic dysfunction (LVSD) and chronic total occlusion (CTO) remain unclear. Methods: From 2014 to 2020, patients with LVSD and CTO who underwent PCI or CABG were collected. The primary endpoint was in-hospital major adverse cardiac or cerebrovascular events (MACCE), defined as the composite of all-cause mortality, cardiovascular mortality, stroke, myocardial infarction (MI), and target vessel revascularization. Inverse probability of treatment weighting (IPTW) was performed to evaluate the association between revascularization strategies and in-hospital outcomes. The hazard ratio (HR) and 95% confidence interval (CI) were calculated using the Cox proportional hazards model. Results: Of the 773 patients who met the inclusion criteria, 543 (70.2%) underwent PCI, and 230 (29.8%) underwent CABG. The primary endpoint was observed in 25 (3.2%) patients. The incidence of in-hospital MACCE (6.5% vs. 1.8%, p < 0.001) was significantly higher in the CABG group than in the PCI group. After IPTW, the risk of in-hospital MACCE was not found to be significantly different between CABG and PCI groups (HR = 1.81; 95% CI: 0.37–8.82; p = 0.460). Compared with patients who underwent PCI, those who underwent CABG exhibited a significantly higher risk of MI (HR = 6.92; 95% CI: 1.24–38.60; p = 0.027). Conclusions: Patients with LVSD and CTO could experience better outcomes with PCI, which offers a safer alternative coronary revascularization strategy and a reduced risk of MI.
References
Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. Journal of the American College of Cardiology. 2002; 39: 210–218.
Ahmad Y, Petrie MC, Jolicoeur EM, Madhavan MV, Velazquez EJ, Moses JW, et al. PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes. Journal of the Society for Cardiovascular Angiography & Interventions. 2022; 1: 100020.
Bollano E, Redfors B, Rawshani A, Venetsanos D, Völz S, Angerås O, et al. Temporal trends in characteristics and outcome of heart failure patients with and without significant coronary artery disease. ESC Heart Failure. 2022; 9: 1812–1822.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145: e895–e1032.
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019; 40: 87–165.
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148: e9–e119.
Yamamoto K, Matsumura-Nakano Y, Shiomi H, Natsuaki M, Morimoto T, Kadota K, et al. Effect of Heart Failure on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Severe Coronary Artery Disease. Journal of the American Heart Association. 2021; 10: e021257.
Völz S, Redfors B, Angerås O, Ioanes D, Odenstedt J, Koul S, et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). European Heart Journal. 2021; 42: 2657–2664.
Kirtane AJ, Doshi D, Leon MB, Lasala JM, Ohman EM, O'Neill WW, et al. Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention. Circulation. 2016; 134: 422–431.
Tajstra M, Pyka Ł, Gorol J, Pres D, Gierlotka M, Gadula-Gacek E, et al. Impact of Chronic Total Occlusion of the Coronary Artery on Long-Term Prognosis in Patients With Ischemic Systolic Heart Failure: Insights From the COMMIT-HF Registry. JACC. Cardiovascular Interventions. 2016; 9: 1790–1797.
Simsek B, Rempakos A, Kostantinis S, Karacsonyi J, Rangan BV, Mastrodemos OC, et al. A Systematic Review of Periprocedural Risk Prediction Scores in Chronic Total Occlusion Percutaneous Coronary Intervention. The American Journal of Cardiology. 2023; 193: 118–125.
Simsek B, Kostantinis S, Karacsonyi J, Alaswad K, Karmpaliotis D, Masoumi A, et al. Outcomes of chronic total occlusion percutaneous coronary intervention in patients with reduced left ventricular ejection fraction. Catheterization and Cardiovascular Interventions. 2022; 99: 1059–1064.
Albaeni A, Chatila KF, Thakker RA, Kumfa P, Alwash H, Elsherbiny A, et al. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Interventions in Heart failure patients. Current Problems in Cardiology. 2023; 48: 101458.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599–3726.
Ybarra LF, Rinfret S, Brilakis ES, Karmpaliotis D, Azzalini L, Grantham JA, et al. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation. 2021; 143: 479–500.
Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. European Heart Journal. 2018; 39: 2192–2207.
Velazquez EJ. Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting to Treat Ischemic Cardiomyopathy? JAMA Cardiology. 2020; 5: 641–642.
Kobayashi N, Ito Y, Kishi K, Muramatsu T, Okada H, Oikawa Y, et al. Procedural results and in-hospital outcomes of percutaneous coronary intervention for chronic total occlusion in patients with reduced left ventricular ejection fraction: Sub-analysis of the Japanese CTO-PCI Expert Registry. Catheterization and Cardiovascular Interventions. 2022; 100: 30–39.
Nombela-Franco L, Mitroi CD, Fernández-Lozano I, García-Touchard A, Toquero J, Castro-Urda V, et al. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study). Circulation. Arrhythmia and Electrophysiology. 2012; 5: 147–154.
Nombela-Franco L, Iannaccone M, Anguera I, Amat-Santos IJ, Sanchez-Garcia M, Bautista D, et al. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis. JACC. Cardiovascular Interventions. 2017; 10: 879–888.
Iannaccone M, Nombela-Franco L, Gallone G, Annone U, Di Marco A, Giannini F, et al. Impact of Successful Chronic Coronary Total Occlusion Recanalization on Recurrence of Ventricular Arrhythmias in Implantable Cardioverter-Defibrillator Recipients for Ischemic Cardiomyopathy (VACTO PCI Study). Cardiovascular Revascularization Medicine: Including Molecular Interventions. 2022; 43: 104–111.
Liao R, Li Z, Wang Q, Lin H, Sun H. Revascularization of chronic total occlusion coronary artery and cardiac regeneration. Frontiers in Cardiovascular Medicine. 2022; 9: 940808.
Behnes M, Mashayekhi K, Kuche P, Kim SH, Schupp T, von Zworowsky M, et al. Prognostic impact of coronary chronic total occlusion on recurrences of ventricular tachyarrhythmias and ICD therapies. Clinical Research in Cardiology. 2021; 110: 281–291.
Sachdeva R, Agrawal M, Flynn SE, Werner GS, Uretsky BF. The myocardium supplied by a chronic total occlusion is a persistently ischemic zone. Catheterization and Cardiovascular Interventions. 2014; 83: 9–16.
Toma A, Stähli BE, Gick M, Gebhard C, Kaufmann BA, Mashayekhi K, et al. Comparison of Benefit of Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients With Versus Without Reduced (≤40%) Left Ventricular Ejection Fraction. The American Journal of Cardiology. 2017; 120: 1780–1786.
Ishida K, Martin-Yuste V, Prat S, Cardona M, Ferreira I, Sabaté M. Prognosis of Patients With Reduced Left Ventricular Ejection Fraction and Chronic Total Occlusion According to Treatment Applied. Cardiovascular Revascularization Medicine: Including Molecular Interventions. 2021; 27: 22–27.
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. The New England Journal of Medicine. 2016; 374: 1511–1520.
Chen YW, Lee WC, Fang HY, Sun CK, Sheu JJ. Coronary Artery Bypass Graft Surgery Brings Better Benefits to Heart Failure Hospitalization for Patients with Severe Coronary Artery Disease and Reduced Ejection Fraction. Diagnostics. 2022; 12: 2233.
Ryan M, Morgan H, Petrie MC, Perera D. Coronary revascularisation in patients with ischaemic cardiomyopathy. Heart. 2021; 107: 612–618.
Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Piña IL, et al. Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. Circulation. 2020; 142: 1725–1735.
Brophy TJ, Warsavage TJ, Hebbe AL, Plomondon ME, Waldo SW, Rao SV, et al. Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program. American Heart Journal. 2021; 235: 149–157.
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. The New England Journal of Medicine. 2011; 364: 1607–1616.
Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1–coronary artery bypass grafting surgery. The Annals of Thoracic Surgery. 2009; 88: S2–S22.
Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. European Journal of Cardio-thoracic Surgery. 2012; 41: 734–744; discussion 744–745.
Seese L, Sultan I, Gleason T, Wang Y, Thoma F, Navid F, et al. Outcomes of Conventional Cardiac Surgery in Patients With Severely Reduced Ejection Fraction in the Modern Era. The Annals of Thoracic Surgery. 2020; 109: 1409–1418.
Daoulah A, Alasmari A, Hersi AS, Alshehri M, Garni TA, Abuelatta R, et al. Percutaneous Coronary Intervention Vs Coronary Artery Bypass Surgery for Unprotected Left Main Coronary Disease: G-LM Registry. Current Problems in Cardiology. 2022; 47: 101002.
Lin S, Guan C, Wu F, Xie L, Zou T, Shi Y, et al. Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion and Multivessel Disease. Circulation. Cardiovascular Interventions. 2022; 15: e011312.
Brennan JM, Curtis JP, Dai D, Fitzgerald S, Khandelwal AK, Spertus JA, et al. Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: results from 1,208,137 procedures in the NCDR (National Cardiovascular Data Registry). JACC. Cardiovascular Interventions. 2013; 6: 790–799.
Bianco V, Kilic A, Mulukutla S, Gleason TG, Kliner D, Allen CC, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with reduced ejection fraction. The Journal of Thoracic and Cardiovascular Surgery. 2021; 161: 1022–1031.e5.
Cabac-Pogorevici I, Muk B, Rustamova Y, Kalogeropoulos A, Tzeis S, Vardas P. Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology. European Journal of Heart Failure. 2020; 22: 789–799.
Parikh PB, Bhatt DL, Bhasin V, Anker SD, Skopicki HA, Claessen BE, et al. Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2021; 77: 2432–2447.
Ji Q, Xia LM, Shi YQ, Ma RH, Shen JQ, Ding WJ, et al. Impact of severe left ventricular dysfunction on in-hospital and mid-term outcomes of Chinese patients undergoing first isolated off-pump coronary artery bypass grafting. Journal of Cardiothoracic Surgery. 2017; 12: 87.
Yan P, Zhang K, Cao J, Dong R. Left Ventricular Structure is Associated with Postoperative Death After Coronary Artery Bypass Grafting in Patients with Heart Failure with Reduced Ejection Fraction. International Journal of General Medicine. 2022; 15: 53–62.
Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. The American Journal of Cardiology. 2009; 103: 355–360.
Wu X, Cai J, Zhang Q, Huang H. Assessing the Clinical Influence of Chronic Total Occlusions (CTOs) Revascularization and the Impact of Vascularization Completeness on Patients with Left Ventricular (LV) Systolic Dysfunction. Computational Intelligence and Neuroscience. 2022; 2022: 9128206.
Pinto G, Fragasso G, Gemma M, Bertoldi L, Salerno A, Godino Md C, et al. Long-term clinical effects of recanalization of chronic coronary total occlusions in patients with left ventricular systolic dysfunction. Catheterization and Cardiovascular Interventions. 2020; 96: 831–838.
